precisionmedicineonline13h
FDA Clears Lion TCR to Begin Phase II Trial of TCR T-Cell Therapy in HBV-Related Liver Cancer
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
Hosted on MSN1d
Lion TCR s Liocyx M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV Related Hepatocellular Carcinoma
On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...
Hosted on MSN1d
BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...